Coagulation protein disease
MONDO:0002242Congenital or acquired deficiency of one of the coagulation factors. It results in bleeding.
Also known as: coagulation factor deficiency, coagulation factor deficiency syndrome
275 clinical trials for this condition and its sub-types, 13 tagged with Coagulation protein disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Coagulation protein disease
-
Hemophilia 55 trials · 214 incl. sub-types
4 sub-types
- Hemophilia A 178 trials Sub-types →
- Hemophilia B 84 trials · 91 incl. sub-types Sub-types →
- Acquired hemophilia 2 trials · 7 incl. sub-types Sub-types →
- Factor XI deficiency 0 trials Sub-types →
-
Von Willebrand disease (hereditary or acquired) 39 trials · 46 incl. sub-types
2 sub-types
- Hereditary von Willebrand disease 18 trials · 29 incl. sub-types Sub-types →
- Acquired von willebrand syndrome 3 trials
-
Acquired coagulation factor deficiency 4 trials · 15 incl. sub-types
6 sub-types
- Acquired hemophilia 2 trials · 7 incl. sub-types Sub-types →
- Acquired von willebrand syndrome 3 trials
- Acquired factor X deficiency 1 trial
- Acquired factor V deficiency 0 trials
- Acquired factor VII deficiency 0 trials
- Acquired factor XIII deficiency 0 trials
-
Factor VII deficiency 6 trials
2 sub-types
- Congenital factor VII deficiency 3 trials
- Acquired factor VII deficiency 0 trials
-
Congenital fibrinogen deficiency 2 trials · 6 incl. sub-types
1 sub-type
- Familial dysfibrinogenemia 2 trials · 6 incl. sub-types Sub-types →
-
Congenital vitamin K-dependent coagulation factors deficiency 0 trials · 4 incl. sub-types
5 sub-types
-
Factor X deficiency 2 trials
2 sub-types
- Acquired factor X deficiency 1 trial
- Congenital factor X deficiency 0 trials
-
Congenital factor XII deficiency 1 trial
-
Hypoplasminogenemia 1 trial
-
East Texas bleeding disorder 0 trials
-
Tatsumi factor deficiency 0 trials
-
Alpha-2-plasmin inhibitor deficiency 0 trials
-
Dysplasminogenemia 0 trials
-
Factor V amsterdam bleeding disorder 0 trials
-
Factor V atlanta bleeding disorder 0 trials
-
Factor V deficiency 0 trials
2 sub-types
- Acquired factor V deficiency 0 trials
- Congenital factor V deficiency 0 trials
-
Factor XIII deficiency 0 trials
2 sub-types
- Acquired factor XIII deficiency 0 trials
- Congenital factor XIII deficiency 0 trials Sub-types →
-
Inherited prekallikrein deficiency 0 trials
-
Plasminogen deficiency, type II 0 trials
Most studied deeper sub-types
-
One-shot gene therapy aims to free hemophilia patients from constant infusions
Disease control CompletedThis trial tests a gene therapy called valoctocogene roxaparvovec for people with severe hemophilia A who have developed inhibitors (antibodies that block standard treatment). The therapy uses a harmless virus to deliver a working copy of the gene for clotting factor VIII, so the…
Phase 1/2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Weekly shot aims to get severe hemophilia patients moving more
Disease control CompletedThis study is testing a new medicine called efanesoctocog alfa in about 90 people aged 12 and older with severe hemophilia A. Participants receive a weekly injection for 24 months to see if it helps them be more physically active and improves joint health. The study uses activity…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
One-Time gene therapy shows promise for hemophilia a
Disease control CompletedThis study tested a one-time gene therapy (valoctocogene roxaparvovec) in 22 adults with severe hemophilia A. The treatment aims to help the body produce its own clotting factor VIII, reducing the need for regular infusions. Participants also received steroids to manage immune re…
Phase 3 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Real-World study tracks Alprolix's bleeding control in hemophilia b
Disease control CompletedThis study followed 151 people with hemophilia B who were already using or starting Alprolix, a long-lasting clotting factor. Over 24 months, researchers tracked how often bleeding occurred, how often the drug was injected, and how much was used. The goal was to see how well Alpr…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hemophilia drug may last longer, reducing need for frequent shots
Knowledge-focused CompletedThis study tested a new drug called efanesoctocog alfa in 24 adults with severe hemophilia A. Researchers compared how long it stays in the body versus two existing drugs. Participants received one dose of their usual drug, then later one dose of the new drug, with blood samples …
Phase 1 • Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC